NESS ZIONA, Israel, Feb. 8, 2018 /PRNewswire/ —BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), developer of a Universal Flu Vaccine candidate currently in preparation for a Phase 3 clinical trial, and the European UNISEC consortium announced today they will co-host the Annual UNISEC Consortium Meeting, which will take place next week in Jerusalem, Israel. Attendees representing the consortium’s partners from academia, government, and industry will discuss achievements towards development of a universal influenza vaccine, including the recent successful results of the Phase 2b clinical trial on BiondVax’s universal flu vaccine candidate M-001. Also expected to attend will be representatives from the U.S. Department of Health and Human Services (HHS).

Dr. Ed Schmidt, Executive Manager of the UNISEC consortium, commented, “UNISEC is pleased to see the significant advancements we have enabled towards improved influenza vaccines. We are grateful to the EU FP7 for their financial support of UNISEC and previous consortia towards this important goal. I also wish to thank the consortium partners for their remarkable collaborative spirit and intensive work.”

Dr. Ron Babecoff, BiondVax’s CEO, noted, “The UNISEC consortium collaboration has been a significant factor in propelling BiondVax’s universal flu vaccine towards our upcoming pivotal Phase 3 trial. We are proud to be part of the UNISEC consortium and honored to host this meeting in Jerusalem.”

Babecoff continued, “Experts report that we are currently experiencing the worst flu season since the 2009 pandemic. There is wide consensus for the urgent need to develop a broadly protective and effective influenza vaccine. BiondVax continues to lead the global effort and hopes to be the first to bring to the world a multi-strain multi-season universal flu vaccine, as our pivotal clinical efficacy Phase 3 trial is starting later this year.”